Grahaem Brown Consulting Ltd

Founder Dr Grahaem Brown

BIOGRAPHY

Dr Grahaem Brown qualified in Medicine at University College Hospital , London and is an accredited specialist in Internal Medicine and in Tropical Medicine.
Before joining the pharmaceutical industry, Grahaem spent 10 years in hospital medicine and two years in a Clinical Research Unit in Malaysia.

He has over 20 years of drug development experience gained in senior positions at UCB, Celltech, Pfizer, Pharmacia, Novartis and Glaxo . He had overall responsibility for the successful clinical development of 20 products across a broad range of therapeutic areas, including anti-infectives, oncology, cardiovascular, neurology, asthma, immunology and transplantation.

Since March '07, he has been a consultant to the Biotech industry, advising companies on Development Strategies, carrying out Due Diligence for investors and advising on Partnering

PROFESSIONAL QUALIFICATIONS

Studied Medicine at University College Hospital London 1963-1967

MB BS 1967, MRCP 1971, DTM&H 1974, FRCP 1990, FFPM 1989

Specialist Accreditation in Internal Medicine (1978) Tropical Medicine (1982)

AREAS of EXPERTISE

Clinical Development - broad experience of designing clinical development strategies and plans; managing execution of large global clinical programs; negotiation with and management of CRO's; interaction with regulators, key opinion leaders and other stakeholders

International Product Development - driving global development of small molecules and biologicals from pre-clinical to clinical, through product launch and life cycle management; allocating and prioritizing resources to manage many projects concurrently and deliver near-simultaneous regulatory submissions. Contributed in a major way to the development of 20 significant products

Risk Evaluation for Investors – conducting scientific / commercial due diligence; assessing potential collaboration opportunities and establishing and managing relationships and collaborations with third-parties from “Biotech” to “Big Pharma”, including co-development as well as in- and out-licensing partnerships

Performance Improvement and Change Management - designing, championing and implementing process re-engineering programs aimed at reducing development times / costs and improving quality; leading demanding people through discontinuity and major change (especially post-merger integration) coaching high-performing development teams and enhancing effective cross-functional and cross-national interfaces